Aquestive Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Aquestive Therapeutics Inc.
- Former names
- MonoSol Rx, Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Warren
- Headquarters state / province
- New Jersey
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- AQST
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001398733
- EIN
- 20-8623253
Board of directors
-
Abigail L. Jenkins · DirectorSince 2024
-
Daniel Barber · Director · President and CEOSince 2025
-
Gregory B. Brown · DirectorSince 2023
-
John Cochran · DirectorSince 2023
-
Julie Krop · DirectorSince 2023
-
Marco Taglietti · DirectorSince 2023
-
Santo J. Costa · DirectorSince 2023
-
Timothy E. Morris · DirectorSince 2023
Chief executives
Daniel Barber
· President and CEO
Dates unknown
Director election results
Annual meeting of June 10, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
100.0%
-
100.0%
-
100.0%
Board connections
3 of this board's directors also sit on 3 other boards.
- via Santo J. Costa
- via Timothy E. Morris
- via Gregory B. Brown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $2,974,076
- 18 sales by 9 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 15, 2026 | Daniel Barber Director, Officer (President and CEO) | Open-market sale | −25,000 | $4.82 | $120,488 |
| Sep 9, 2026 | Boyd Peter E. Officer (Chief People Officer) | In-the-money exercise | +2,293 | $0.96 | $2,201 |
| Sep 9, 2026 | Korczynski Sherry Officer (Chief Commercial Officer) | Option exercise | +8,750 | $2.65 | $23,188 |
| Sep 9, 2026 | Korczynski Sherry Officer (Chief Commercial Officer) | Open-market sale | −8,750 | $5.22 | $45,675 |
| Sep 8, 2026 | Daniel Barber Director, Officer (President and CEO) | In-the-money exercise | +91,743 | $0.96 | $88,073 |
| Sep 3, 2026 | Jung Cassie Officer (Chief Operating Officer) | In-the-money exercise | +4,587 | $0.96 | $4,404 |
| Aug 17, 2026 | Daniel Barber Director, Officer (President and CEO) | Open-market sale | −25,000 | $4.29 | $107,168 |
| Aug 14, 2026 | Korczynski Sherry Officer (Chief Commercial Officer) | Shares withheld for tax | −2,714 | $4.25 | $11,535 |
| Jul 16, 2026 | Daniel Barber Officer (President and CEO) | Open-market sale | −20,369 | $4.00 | $81,509 |
| Jul 15, 2026 | Daniel Barber Officer (President and CEO) | Open-market sale | −4,631 | $4.03 | $18,683 |
| Jun 23, 2026 | Julie Krop Director | Option exercise | +25,000 | $0.71 | $17,750 |
| Jun 23, 2026 | Julie Krop Director | Open-market sale | −25,000 | $5.02 | $125,500 |
| Jun 15, 2026 | Daniel Barber Officer (President and CEO) | Open-market sale | −25,000 | $4.16 | $104,000 |
| Jun 8, 2026 | Korczynski Sherry Officer (Chief Commercial Officer) | Shares withheld for tax | −2,714 | — | — |
| May 18, 2026 | Zalewski Thomas A. Officer (Chief Legal Officer) | Grant or award | +100,000 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.